Related Experiment Video

Updated: Apr 12, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.5K

Combretastatin A4-phosphate and its potential in veterinary oncology: a review

E Abma1, S Daminet1, P Smets1

  • 1Department of Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

Veterinary and Comparative Oncology
|May 20, 2015
PubMed

Insights

Vascular disrupting agents (VDAs) offer a new approach to cancer treatment by targeting tumor stroma. This article explores combretastatin A4-phosphate (CA4P) in veterinary oncology, focusing on side effects and management.

Area of Science:

  • Veterinary Oncology
  • Pharmacology

Background:

  • Traditional anticancer therapies focus on direct cancer cell targeting with limited success.
  • Emerging research investigates targeting tumor stroma, including the use of vascular disrupting agents (VDAs).

Purpose of the Study:

  • To review the history and biology of combretastatin A4-phosphate (CA4P), a VDA.
  • To concentrate on the potential side effects of CA4P in veterinary patients.
  • To discuss the pathogenesis, prevention, and treatment of these side effects.

Main Methods:

  • Literature review on combretastatin A4-phosphate (CA4P).
  • Analysis of VDA mechanisms and clinical applications.
  • Discussion of side effect profiles in veterinary oncology.

Main Results:

  • Combretastatin A4-phosphate (CA4P) is a promising VDA with potential in cancer therapy.
  • Understanding and managing side effects is crucial for veterinary application.
  • Further research is needed to optimize CA4P use in animals.

Conclusions:

  • Vascular disrupting agents (VDAs) like CA4P represent a novel strategy in anticancer therapy.
  • Careful consideration of side effect management is essential for successful veterinary use.
  • CA4P shows potential for treating cancer in veterinary patients.
Keywords:
anticancer therapycombretastatin A4-phosphatetubulin-binding agentvascular disrupting agent

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

12.1K
Using the BLT Humanized Mouse as a Stem Cell based Gene Therapy Tumor Model06:59

Using the BLT Humanized Mouse as a Stem Cell based Gene Therapy Tumor Model

Published on: December 18, 2012

19.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K